Investigating how a specific receptor helps repair lungs after viral infections.
Official title: Endothelial S1PR1 promotes lung repair in post-viral ARDS
Funded at Massachusetts General Hospital · NIH-10948951 · Data updated 2026-11-12
This study is looking at how a specific receptor in the cells lining your lungs can help them heal after viral infections like COVID-19, with the goal of finding new ways to support recovery and prevent lasting lung problems.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $161,240 |
| NIH project number | 1K01HL174822-01 |
| Project ID | NIH-10948951 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced ARDS as a result of viral infections, particularly those related to COVID-19.
✕Less likely to help
Patients who have not experienced ARDS or those with other underlying lung conditions may not benefit from this research.
What this research studies
This research focuses on understanding how the sphingosine-1-phosphate receptor 1 (S1PR1) on endothelial cells contributes to lung repair following viral infections like COVID-19. The study aims to explore the mechanisms by which S1PR1 signaling can promote healing in the lungs and prevent long-term complications such as fibrosis. By examining the pathways involved in this process, the researchers hope to identify potential therapeutic strategies to enhance lung recovery in patients who have experienced acute respiratory distress syndrome (ARDS) due to viral infections.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve lung healing and reduce the risk of long-term complications in patients recovering from viral infections.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways for lung repair, indicating potential for success in this approach.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Brazee, Patricia Louise — Massachusetts General Hospital
- Study coordinator: Brazee, Patricia Louise
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Lipid-gene Profiles in Septic ARDS
A Mayo Clinic team is studying how dysfunctional HDL in sepsis relates to different ARDS patient outcomes, aiming to find features that could guide better treatment.
-
Improving blood vessel repair after pediatric ARDS
Aims to better repair the lungs of children who have ARDS by delivering targeted therapy to lung blood vessels using tiny nanoparticles.
-
NOX4 links to ARDS risk and progression
Aims to understand how NOX4-driven cell damage may make some adults with ARDS worse off and how this could lead to earlier, targeted care.
-
Leading causes of death in alcoholic ARDS patients using clinical data
This project uses big clinical data and AI to find the main factors that cause death in adults with ARDS who have alcohol use issues, aiming to improve understanding and care.
-
Targeting aging-related blood vessel injury to prevent ARDS in older lungs
Aims to find ways to protect lung blood vessels in older adults to prevent dangerous lung swelling (ARDS).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.